Thermo Fisher Scientific (TMO) drew fresh attention after reporting quarterly revenue and earnings that exceeded analyst expectations, alongside completing a large Parkinson's proteomics project with The Michael J. Fox Foundation.

Thermo Fisher Scientific's recent earnings beat and the completion of the Parkinson's proteomics project have coincided with strong momentum, including a 16.6% 30 day share price return and a 24.5% 1 year total shareholder return. This suggests investors are reassessing growth potential and research exposure.

If this kind of life sciences momentum interests you, it can be useful to also look at companies building the digital and hardware backbone behind advanced research, including 56 AI infrastructure stocks

After a 16.6% move over the past 30 days and a 24.5% total return over the past year, Thermo Fisher Scientific now trades only slightly below analyst price targets. Is most of the easy upside already behind the stock, or is it not yet reflected in the valuation?

Most Popular Narrative: 3.9% Overvalued

Thermo Fisher Scientific last closed at $613.54, compared with a widely followed narrative fair value of $590.77 that is based on detailed cash flow assumptions and analyst forecasts.

Ongoing strategic M&A and capacity expansion (for example, the Solventum acquisition), combined with resilient end-market exposure to pandemic preparedness, diagnostics, and emerging market healthcare investment, positions the company for compounding top-line gains and elevated returns on capital as secular demand trends accelerate.

Want to see what sits behind that confident growth story and fair value for Thermo Fisher Scientific? The narrative leans heavily on specific revenue, margin and earnings compounding assumptions plus a premium earnings multiple that has been carefully reverse engineered from today’s price. The full narrative lays out how those moving parts are expected to interact over time and what has to go right for the $590.77 figure to hold.

Result: Fair Value of $590.77 (OVERVALUED)

However, Thermo Fisher Scientific still faces questions about long term organic growth targets and sensitivity to weaker demand from academic, government and China related customers, which could pressure that narrative.

Another View: SWS DCF Fair Value For Thermo Fisher Scientific

The narrative fair value pegs Thermo Fisher Scientific at $590.77 and describes the stock as 3.9% overvalued. Our DCF model instead estimates fair value at $637.99, which is about 3.8% above the current $613.54 share price and therefore suggests TMO may be modestly undervalued. Which lens do you trust more when the gap is this small?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Thermo Fisher Scientific for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The mix of optimism and concern around Thermo Fisher Scientific is clear, so move quickly, review the underlying data and decide where you stand. To see how that balance of risk and opportunity currently looks, take a closer look at the 2 key rewards and 1 important warning sign

Looking for more Thermo Fisher Scientific investment ideas?

If you stop with Thermo Fisher Scientific, you risk missing other opportunities. Use the Simply Wall St screener to quickly surface fresh, high conviction stock ideas.

• Target reliable cash generators by reviewing companies in the solid balance sheet and fundamentals stocks screener (50 results) that can better withstand tough conditions and still fund future growth.
• Hunt for mispriced opportunities using the 52 high quality undervalued stocks to spot stocks where fundamentals and current prices appear out of sync.
• Prioritise stability and sleep better at night by focusing on companies identified in the 78 resilient stocks with low risk scores with more resilient business profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.